Maxcyte (MXCT) Amortization of Deferred Charges (2023 - 2026)

Maxcyte (MXCT) has 4 years of Amortization of Deferred Charges data on file, last reported at $221000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 22.1% year-over-year to $221000.0 in Q1 2026; TTM through Mar 2026 was $842000.0, a 55.93% increase from a year earlier, with the FY2025 full-year figure at $802000.0, up 68.84% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $221000.0, up from $215000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for MXCT reached as high as $221000.0 in Q1 2026 and fell as low as $94000.0 in Q2 2023.
• Historically, Amortization of Deferred Charges has averaged $145615.4 across 4 years, with a median of $120000.0 in 2024.
• Across the five-year window, Amortization of Deferred Charges gained 11.93% in 2024 and surged 76.23% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $109000.0 in 2023, then gained by 11.93% to $122000.0 in 2024, then jumped by 76.23% to $215000.0 in 2025, then climbed by 2.79% to $221000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $221000.0 in Q1 2026, $215000.0 in Q4 2025, and $209000.0 in Q3 2025.